Details
Stereochemistry | RACEMIC |
Molecular Formula | C18H23NO3.ClH |
Molecular Weight | 337.841 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.C[C@H](COC1=CC=CC=C1)N[C@H](C)[C@@H](O)C2=CC=C(O)C=C2
InChI
InChIKey=QVPSGVSNYPRFAS-BQZDIUEZSA-N
InChI=1S/C18H23NO3.ClH/c1-13(12-22-17-6-4-3-5-7-17)19-14(2)18(21)15-8-10-16(20)11-9-15;/h3-11,13-14,18-21H,12H2,1-2H3;1H/t13-,14-,18-;/m1./s1
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C18H23NO3 |
Molecular Weight | 301.3801 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugs.com/cdi/isoxsuprine.htmlCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22893038 | https://www.ncbi.nlm.nih.gov/pubmed/16388203 | https://www.ncbi.nlm.nih.gov/pubmed/11445487 | https://www.ncbi.nlm.nih.gov/pubmed/2874205
Sources: https://www.drugs.com/cdi/isoxsuprine.html
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22893038 | https://www.ncbi.nlm.nih.gov/pubmed/16388203 | https://www.ncbi.nlm.nih.gov/pubmed/11445487 | https://www.ncbi.nlm.nih.gov/pubmed/2874205
Isoxsuprine (used as isoxsuprine hydrochloride) is a drug used as a vasodilator in humans (under the trade name Duvadilan) and equines. Isoxsuprine is a β2 adrenoreceptor agonist that causes direct relaxation of uterine and vascular smooth muscle via β2 receptors. Isoxsuprine it is used in humans for treatment of premature labor, i.e. a tocolytic, and as a vasodilator for the treatment of cerebral vascular insufficiency, Raynaud's phenomenon, and other conditions. Isoxsuprine may increase the heart rate, cause changes in blood pressure, and irritate the GI tract. It should, therefore, be used with caution if combined with other drugs that affect blood pressure, such as sedatives and anesthetic drugs. Isoxsuprine is most commonly used to treat hoof-related problems in the horse, most commonly for laminitis and navicular disease, as its effects as a vasodilator are thought to increase circulation within the hoof to help counteract the problems associated with these conditions.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Effect of intravenous infusion of betasympathomimetic agents on plasma renin activity during pregnancy. | 1978 Nov |
|
Therapeutic effects of high-dose isoxsuprine in the management of mixed-type impotence. | 2001 Jul |
|
Tricuspid regurgitation in a pair of twins at birth secondary to antenatal indomethacin. | 2001 Oct |
|
Isoxsuprine hydrochloride in the horse: a review. | 2002 Apr |
|
Fluorimetric determination of isoxsuprine hydrochloride in pharmaceuticals and biological fluids. | 2002 Apr 15 |
|
A simple kinetic spectrophotometric method for the determination of isoxsuprine in dosage forms. | 2002 Aug |
|
Enantioseparation of chiral vasodilator drug isoxsuprine in high-performance liquid chromatography and capillary electrophoresis. | 2002 Jan 1 |
|
The history of tocolysis. | 2003 Apr |
|
A comparative study between nifedipine and isoxsuprine in the suppression of preterm labour. | 2003 Apr-Jun |
|
Enzyme-linked immunosorbent assay development for the beta-adrenergic agonist zilpaterol. | 2004 Apr 21 |
|
Infectious and uterus related complications during pregnancy and development of atopic and nonatopic asthma in children. | 2004 Jan |
|
A GC-MS method for the determination of isoxsuprine in biological fluids of the horse utilizing electron impact ionization. | 2004 Jan-Feb |
|
Evaluation of MISPE for the multi-residue extraction of beta-agonists from calves urine. | 2004 May 5 |
|
An analgesic evaluation of isoxsuprine in horses. | 2004 Sep-Oct |
|
Search of chemical scaffolds for novel antituberculosis agents. | 2005 Apr |
|
Design, synthesis and evaluation of racemic 1-(4-hydroxyphenyl)-2-[3-(substituted phenoxy)-2-hydroxy-1-propyl]amino-1-propanol hydrochlorides as novel uterine relaxants. | 2005 Aug 1 |
|
Qualitative and quantitative analysis of illicit drug mixtures on paper currency using Raman microspectroscopy. | 2005 Dec |
|
Determination of beta-agonists in liver and retina by liquid chromatography-tandem mass spectrometry. | 2005 Jan-Feb |
|
Determination of beta-agonist residues in bovine urine using liquid chromatography-tandem mass spectrometry. | 2005 Jan-Feb |
|
Determination of isoxsuprine hydrochloride by sequential injection visible spectrophotometry. | 2005 Jun-Jul |
|
Development of a monoclonal antibody-based enzyme-linked immuosorbent assay for the beta-adrenergic agonist zilpaterol. | 2005 May 4 |
|
Synthesis and evaluation of uterine relaxant activity for a novel series of substituted p-hydroxyphenylethanolamines. | 2006 Oct 1 |
|
Use of isoxsuprine for treatment of clinical signs associated with presumptive atherosclerosis in a yellow-naped Amazon parrot (Amazona ochrocephala auropalliata). | 2007 Sep |
|
Effects of alcohols on CE enantioseparation of basic drugs with native gamma-CD as chiral selector. | 2008 Aug |
|
[Multi-residue analysis of 10 beta2-agonists in animal tissues using gas chromatography-mass spectrometry]. | 2008 Jan |
|
A highly sensitive assay for ritodrine in human serum by hydrophilic interaction chromatography-tandem mass spectrometry. | 2008 Jan 1 |
|
Prophylactic oral betamimetics for preventing preterm labour in singleton pregnancies. | 2008 Jan 23 |
|
Pharmacokinetics of isoxsuprine hydrochloride administered orally and intramuscularly to female healthy volunteers. | 2009 |
|
Rapid determination of ractopamine residues in edible animal products by enzyme-linked immunosorbent assay: development and investigation of matrix effects. | 2009 |
|
Use of isoxsuprine hydrochloride as a tocolytic agent in the treatment of preterm labour: a systematic review of previous literature. | 2010 |
|
Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories. | 2010 Apr |
|
Management of pregnant female with meningioma for craniotomy. | 2010 Jan |
|
Simultaneous determination of ritodrine and isoxsuprine using coupling technique of synchronous fluorimetry and H-point standard addition method. | 2010 Jan |
|
Investigation of ractopamine-imprinted polymer for dispersive solid-phase extraction of trace beta-agonists in pig tissues. | 2010 Jul |
|
Spectrophotometric determination of isoxsuprine hydrochloride using 3-methyl-2-benzothiazolinone hydrazone hydrochloride in spiked human urine and pharmaceuticals. | 2010 Jun 15 |
|
Investigation of ractopamine molecularly imprinted stir bar sorptive extraction and its application for trace analysis of beta2-agonists in complex samples. | 2010 May 28 |
|
Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. | 2010 Sep |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2874205
Human myometrial strips were obtained from uteri at the time of cesarean section. The tissues were homogenized in 10 volume of buffer containing 10 mM Tris. HC1 0.25 M sucrose, 1 mM EDTA and 3mM MgCk, pH 7.4, using an Ultra-Turrax PRUhomogenizer. The homogenate was passed through four layers of gauze and centrifuged at 600 x g for 10 min at 4 °C to remove unbroken cells and connective tissue. The supernatant was centrifuged twice at 48 000 χ g for 20 min, with washing of the intermediate pellet. The final pellet was resuspended in assay buffer (50 mM Tris. HC1, 3 mM MgCk, pH 7.4). The membrane preparations were stored in liquid nitrogen until used. 100 μΐ aliquots of the membrane fraction were prepared in triplicate and incubated with 6 nM [3H]-DHA and the increasing concentration of the displacing agent (Isoxsuprine) in a final volume of 300 μΐ assay buffer. After incubation for 20 min at 25 °C, 2 ml of icecold buffer were added and immediately filtered over glassfiber filters
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:01:21 GMT 2023
by
admin
on
Fri Dec 15 15:01:21 GMT 2023
|
Record UNII |
V74TEQ36CO
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29707
Created by
admin on Fri Dec 15 15:01:21 GMT 2023 , Edited by admin on Fri Dec 15 15:01:21 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
82033
Created by
admin on Fri Dec 15 15:01:21 GMT 2023 , Edited by admin on Fri Dec 15 15:01:21 GMT 2023
|
PRIMARY | RxNorm | ||
|
73415938
Created by
admin on Fri Dec 15 15:01:21 GMT 2023 , Edited by admin on Fri Dec 15 15:01:21 GMT 2023
|
PRIMARY | |||
|
3106
Created by
admin on Fri Dec 15 15:01:21 GMT 2023 , Edited by admin on Fri Dec 15 15:01:21 GMT 2023
|
PRIMARY | |||
|
V74TEQ36CO
Created by
admin on Fri Dec 15 15:01:21 GMT 2023 , Edited by admin on Fri Dec 15 15:01:21 GMT 2023
|
PRIMARY | |||
|
CHEMBL1197051
Created by
admin on Fri Dec 15 15:01:21 GMT 2023 , Edited by admin on Fri Dec 15 15:01:21 GMT 2023
|
PRIMARY | |||
|
100000086440
Created by
admin on Fri Dec 15 15:01:21 GMT 2023 , Edited by admin on Fri Dec 15 15:01:21 GMT 2023
|
PRIMARY | |||
|
DTXSID1045328
Created by
admin on Fri Dec 15 15:01:21 GMT 2023 , Edited by admin on Fri Dec 15 15:01:21 GMT 2023
|
PRIMARY | |||
|
209-443-6
Created by
admin on Fri Dec 15 15:01:21 GMT 2023 , Edited by admin on Fri Dec 15 15:01:21 GMT 2023
|
PRIMARY | |||
|
1354003
Created by
admin on Fri Dec 15 15:01:21 GMT 2023 , Edited by admin on Fri Dec 15 15:01:21 GMT 2023
|
PRIMARY | |||
|
579-56-6
Created by
admin on Fri Dec 15 15:01:21 GMT 2023 , Edited by admin on Fri Dec 15 15:01:21 GMT 2023
|
PRIMARY | |||
|
DBSALT001553
Created by
admin on Fri Dec 15 15:01:21 GMT 2023 , Edited by admin on Fri Dec 15 15:01:21 GMT 2023
|
PRIMARY | |||
|
m6555
Created by
admin on Fri Dec 15 15:01:21 GMT 2023 , Edited by admin on Fri Dec 15 15:01:21 GMT 2023
|
PRIMARY | Merck Index | ||
|
757067
Created by
admin on Fri Dec 15 15:01:21 GMT 2023 , Edited by admin on Fri Dec 15 15:01:21 GMT 2023
|
PRIMARY | |||
|
C47576
Created by
admin on Fri Dec 15 15:01:21 GMT 2023 , Edited by admin on Fri Dec 15 15:01:21 GMT 2023
|
PRIMARY | |||
|
V74TEQ36CO
Created by
admin on Fri Dec 15 15:01:21 GMT 2023 , Edited by admin on Fri Dec 15 15:01:21 GMT 2023
|
PRIMARY | |||
|
SUB02808MIG
Created by
admin on Fri Dec 15 15:01:21 GMT 2023 , Edited by admin on Fri Dec 15 15:01:21 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|